🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

How can AI improve treatment response prediction in neuroendocrine tumors? The RAISE project analyzed CT scans from the CLARINET trial to explore new endpoints for earlier progression-free survival (PFS) prediction. Watch the video here: hubs.ly/Q0351qNL0 #NET #AI #Oncology

As #PulmonaryArterialHypertension (PAH) progresses, the arteries stiffen, and pulmonary arterial compliance (PAC) is reduced. Decreased PAC has been shown to be a significant predictor of mortality in PAH. Learn more: hubs.ly/Q035dpnR0 United Therapeutics Medical #PulmonaryHypertension

Response heterogeneity could serve as a biomarker for neuroendocrine tumor treatment response. Learn how the RAISE project evaluated this using AI and CT scan data from the CLARINET trial. Watch now: hubs.ly/Q0351rwz0 #NeuroendocrineTumors #AI #RAISEProject #Oncology

A 24-week sub-study of the FREEDOM-EV clinical study suggested that increased compliance contributes to the physiological mechanism by which oral treprostinil delays disease progression in #PulmonaryArterialHypertension. hubs.ly/Q035LF_S0 United Therapeutics Medical #PulmonaryHypertension

RECIST criteria may underestimate treatment response in slow-growing neuroendocrine tumors. The RAISE project explored AI-driven methods to address this challenge. Watch the video to learn about the findings: hubs.ly/Q035-PgP0 #NeuroendocrineTumors #AI #RAISEProject

Watch the video below to learn about the relationship between pulmonary arterial compliance (PAC) and #PulmonaryArterialHypertension (PAH), and how oral trepostinil delays disease progression in PAH by increasing PAC. hubs.ly/Q035LFNR0 United Therapeutics Medical #PulmonaryHypertension

Explore the latest in GPP prevention! The EFFISAYIL® 2 trial evaluated spesolimab’s ability to reduce flare risk and improve quality of life for patients with GPP. Watch Prof. Akimichi Morita present the findings here: hubs.ly/Q037x50P0 #Psoriasis #GPP #RareDisease

Neuroendocrine tumors grow slowly, making treatment response challenging to measure with RECIST criteria. The RAISE project explored AI-based methods to predict progression-free survival earlier. Watch the animated video to learn more: hubs.ly/Q035-JLH0 #AI #Oncology

This video describes how increasing pulmonary arterial compliance using oral treprostinil can delay disease progression in #PulmonaryArterialHypertension (PAH), as revealed in a sub-study of the FREEDOM-EV clinical study. hubs.ly/Q035LG0R0 United Therapeutics Medical #PulmonaryHypertension

Until recently, there were no approved therapies to prevent GPP flares. The EFFISAYIL® 2 trial investigated how spesolimab could change that. Learn more in this video article with Prof. Akimichi Morita: hubs.ly/Q037xnXk0 #Psoriasis #GPP #Dermatology #RareDisease

With 123 participants across 20 countries, the EFFISAYIL® 2 trial demonstrated that spesolimab helps prevent GPP flares and sustain quality of life. Watch Prof. Akimichi Morita discuss the results: hubs.ly/Q037xkqB0 #Psoriasis #GPP #Dermatology #RareDisease

Learn how spesolimab, a targeted IL-36 receptor blocker, helped reduce GPP flares over 48 weeks in the EFFISAYIL® 2 trial. Watch Prof. Akimichi Morita present the key findings here: hubs.ly/Q037x5MD0 #Psoriasis #GPP #Dermatology #RareDisease

The HIMALAYA study found STRIDE (tremelimumab + durvalumab) extended survival in patients with unresectable hepatocellular carcinoma. Could this be a new standard of care? Watch the animated video to find out! bit.ly/3DPRukj #LiverCancer #HCC #Oncology #Cancer

For years, sorafenib has been the standard for unresectable hepatocellular carcinoma (HCC), but side effects can impact quality of life. HIMALAYA explored STRIDE as an alternative, offering better outcomes. Learn more in our video! bit.ly/43FGTD3 #LiverCancer #HCC

The HIMALAYA study explored tremelimumab + durvalumab (STRIDE) for unresectable hepatocellular carcinoma. See how it performed compared to sorafenib in this animated video: bit.ly/3E1jqlb #LiverCancer #HCC #Oncology #Cancer

Tremelimumab & durvalumab (STRIDE) offer new hope for patients with unresectable hepatocellular carcinoma. The HIMALAYA study results support this new approach, watch the animated video to learn more! bit.ly/3QZXDgK #LiverCancer #HCC #Oncology #Cancer

Biliary tract cancers (BTCs) treatment is evolving! The phase III TOPAZ-1 study evaluated durvalumab + chemotherapy for advanced BTC. Results show improved survival without added side effects. Watch the video to learn more: hubs.ly/Q03fj55k0 #BTCawareness #CancerTreatment

Biliary tract cancers (BTCs) are often diagnosed late, making treatment challenging. The TOPAZ-1 trial explored adding durvalumab to chemotherapy, results show longer survival & better outcomes. Watch the findings here: hubs.ly/Q03fhYCr0 #BTCawareness #CancerTreatment

A new option for advanced BTC! The TOPAZ-1 trial found that durvalumab + chemotherapy improves survival compared to chemotherapy alone. Discover the impact of this combination therapy in our animated video: hubs.ly/Q03fhWPn0 #BTCawareness #CancerTreatment #BTC #Oncology

Biliary tract cancer treatment has relied on chemotherapy, but outcomes remain poor. The phase III TOPAZ-1 study highlights how durvalumab + chemo offers new hope. Learn more about this breakthrough in our video article: hubs.ly/Q03fh_dR0 #BTCawareness #CancerTreatment